<DOC>
	<DOC>NCT02117219</DOC>
	<brief_summary>This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome after treatment with hypomethylating agents</brief_summary>
	<brief_title>Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome</brief_title>
	<detailed_description>A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death-1 ligand 1 [PD-L1]) to evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI4736 as monotherapy or in combination with Tremelimumab with or without Azacitidine in adult patients with myelodysplastic syndrome.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Adult male or female subjects with pathologically confirmed MDS who failed to respond, relapsed after an initial response, or were unable to tolerate hypomethylating agents, ECOG performance status of 0 2, and adequate organ and marrow function. Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment, prior MAb against CTLA4, PD1, or PDL1, alllogenic or haploidentical transplant, current immunosuppressive medication or autoimmune or inflammatory disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>